LFL2-Targeting Antibodies for Cancer Stroma Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer diagnosis and treatment methods are inadequate due to the difficulty in effectively detecting and targeting cancer cells, particularly in solid tumors, where high interstitial fluid pressure hampers drug delivery and existing therapies induce significant side effects.
Innovation Solution
Development of antibodies specifically targeting the LFL2 protein, which is highly expressed in cancer stroma, allowing for the diagnosis, prognosis, and therapeutic intervention in various cancers by inhibiting cancer cell proliferation, enhancing chemotherapeutic drug delivery, and serving as a biomarker for cancer monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies (chemotherapy, radiation therapy) are used to treat cancer, then cancer cells can be killed, but serious side effects are induced that diminish quality of life
Solution Approach 1:
The patent uses LFL2 protein as an intermediary target that is specifically expressed in cancer stroma but not in normal adult tissues. By directing therapeutic antibodies against this intermediary marker, the treatment achieves cancer-specific killing while sparing normal tissues, thereby reducing side effects while maintaining treatment efficacy
Solution Approach 2:
The invention exploits the local quality difference between cancer tissue and normal tissue through LFL2 expression patterns. The protein is highly expressed in cancer stroma and tumor-associated tissues but absent or minimally expressed in normal adult tissues, allowing localized targeting of therapy to cancer sites while preserving normal tissue function and reducing systemic side effects
2Reliability
If high interstitial fluid pressure in solid tumors is present, then tumor growth occurs, but drug delivery to cancer cells is hampered
Solution Approach 1:
The patent targets LFL2 protein in the tumor stroma as an intermediary structure that supports tumor growth and maintains high interstitial fluid pressure. By using antibodies against LFL2, the treatment indirectly addresses the pressure problem by disrupting the stromal support network, which can normalize tumor vasculature and reduce interstitial pressure, thereby improving drug delivery without directly confronting the pressure barrier
Solution Approach 2:
The invention employs preliminary action by first targeting and disrupting the LFL2-expressing stromal network that creates the high interstitial fluid pressure environment. This preliminary disruption of the tumor microenvironment precedes and facilitates subsequent chemotherapy delivery, making the tumor more permeable and accessible to therapeutic agents
3Reliability
If LFL2 protein is highly expressed in cancer stroma, then it can serve as a therapeutic target, but it is also expressed in placental cells which are dispensable for life
Solution Approach 1:
The patent converts the potential harm of LFL2 expression in placental cells into a benefit by recognizing that reproductive organs are dispensable for life in the context of cancer treatment. The high expression of LFL2 in placenta, while limiting universal application, actually provides a highly specific target in cancer stroma with minimal risk to essential life functions, making it an advantageous target for immunotherapy despite the placental expression
Solution Approach 2:
The invention exploits parameter changes in LFL2 expression levels across different tissue types and disease states. While LFL2 is expressed in placental cells under normal conditions, its expression is dramatically upregulated in cancer stroma. This parameter change in expression level provides the specificity needed for cancer targeting, as the high expression in tumor tissue distinguishes it from the baseline placental expression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LFL2-targeting antibodies effectively inhibit cancer cell proliferation, improve chemotherapy efficacy by reducing tumor interstitial fluid pressure, and provide a reliable biomarker for monitoring cancer progression and treatment efficacy.
Implementation Method 1
anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
Data Source
AI summary
Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.